Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
Brittany A BruchNatalie K KetchenLeah N RasmussenAlyssa R BartelsSachinkumar B SinghPublished in: Pediatric pulmonology (2021)
We suggest that ELX/TEZ/IVA may improve fat-soluble vitamin absorption, specifically serum 25-hydroxyvitamin D. These results may lead to adjustments in vitamin supplementation in patients receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. This article is protected by copyright. All rights reserved.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- lung function
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- adipose tissue
- prognostic factors
- peritoneal dialysis
- chronic obstructive pulmonary disease
- patient reported outcomes
- mesenchymal stem cells
- bone marrow
- smoking cessation
- replacement therapy